Everyone in the biotech and life sciences industries knows that 21 CFR Part 11 is not a new requirement ‘ it dates back to 1997, and has remained pretty much unchanged since then. Only its scope has changed.

Initially, the new requirement was widely ignored by both the industry and the FDA. This indifference was not intentional, but can be attributed to a pure lack of understanding by both the industry and the regulators. (more…)